Legend Biotech (LEGN) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Legend Biotech has reported positive outcomes from the Phase 3 CARTITUDE-4 trial, showing that its cell therapy CARVYKTI® significantly improves overall survival in patients with relapsed and lenalidomide-refractory multiple myeloma. The results, which add to the evidence supporting CARVYKTI®’s benefits, will be used for global regulatory label updates following its recent FDA approval for multiple myeloma treatment after at least one prior therapy. Safety profiles remained consistent with no new concerns, reinforcing the therapy’s promise for patients with this incurable disease.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- ‘The Big Vote Coming’: Daniel Ives Weighs In on Tesla Stock as Shareholders Decide Musk’s $1 Trillion Pay Package
- ‘Time to Get Off This Train,’ Says Top Analyst About Rigetti Computing Stock Ahead of Earnings
- AMD Stock Heads Into Tuesday’s Earnings With Momentum — Here’s What This Top Investor Expects